im92 car-t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 15, 2022 (NCT05275062)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05275062 | Early Phase 1 (Phase 1) | Feb 15, 2022 | Beijing Immunochina Medical Science & Technology Co., Ltd., People's Liberation Army of China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Immunochina Medical Science & Technology Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1